Risk factors analysis for pneumocystis jiroveci pneumonia (PCP) in patients with haematological malignancies and pneumonia

Scandinavian Journal of Infectious Diseases

Volumn 36, Issue 11-12, 2004, Pages 848-854

  Roblot, France ^a   Imbert, Sabrina ^a   Godet, Cendrine ^a   Kauffmann, Catherine ^a   Ragot, Stephanie ^a   Le Moal, Gwenael ^a   Roblot, Pascal ^a   Rodier, Marie Helene ^a   Robert, Rene ^a   Becq Giraudon, Bertrand ^a   Guilhot, Francois ^a  

^a POITIERS UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYTARABINE; FLUDARABINE; IDARUBICIN; METHOTREXATE; PREDNISOLONE; PREDNISONE; VINCRISTINE;

ADULT; AGED; ARTICLE; CASE CONTROL STUDY; CLINICAL ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; CYTOCHEMISTRY; FEMALE; HEMATOLOGIC MALIGNANCY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOFLUORESCENCE; LUNG LAVAGE; LYMPHOCYTE COUNT; MALE; PNEUMOCYSTIS JIROVECI; PNEUMOCYSTIS PNEUMONIA; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; STATISTICAL ANALYSIS;

ADULT; AGED; BRONCHOALVEOLAR LAVAGE FLUID; CASE-CONTROL STUDIES; FEMALE; HEMATOLOGIC NEOPLASMS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; PNEUMOCYSTIS JIROVECI; PNEUMONIA; PNEUMONIA, PNEUMOCYSTIS; RESPIRATION, ARTIFICIAL; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 19944429391     PISSN: 00365548     EISSN: None     Source Type: Journal    
DOI: 10.1080/00365540410021180     Document Type: Article

References (46)

1. Sidhu GS, Cassai ND, Pei Z. Pneumocystis carinii: an update. Ultrastruct Pathol 2003; 27: 115-22.
2. Totet A, Respaldiza N, Pautard JC, Raccurt C, Nevez G. Pneumocystis jiroveci genotypes and primary infection. Clin Infect Dis 2003; 36: 1340-2.
3. Dutz W. Pneumocystis carinii pneumonia. Pathol Annu 1970; 5: 309-41.
4. Burke B, Good R. Pneumocystis carinii infection. Medicine 1973; 52: 23-51.
5. Walzer P, Perl D, Krogstad D, Rawson PG, Schultz MG. Pneumocystis carinii pneumonia in the United States: epidemiological, clinical and diagnostic features. Ann Intern Med 1974; 80: 83-93.
6. Vogel CL, Cohen MH, Powell RD Jr, De Vita VT. Pneumocystis carinii pneumonia. Ann Intern Med 1968; 68: 97-108.
7. Le Clair RA. Descriptive epidemiology of interstitial Pneumocystis carinii pneumonia: an analysis of 107 cases from the United States. Am Rev Respir Dis 1969; 99: 542-7.
8. Roblot F, Godet C, Le Moal G, Garo B, Faouzi Souala M, Dary M, et al. Analysis of underlying diseases and prognosis factors associated with Pneumocystis carinii pneumonia in immuno-compromized HIN-negative patients. Eur J Clin Microbiol Infect Dis 2002; 21: 523-31.
9. Hughes WT, Feldman S, Aur RJ, Verzosa MS, Hustu HO, Simone JV. Intensity of immunosuppressive therapy and the incidence of Pneumocystis carinii pneumonitis. Cancer 1975; 36: 2004-9.
10. Arend SM, van't Wout JW. Prophylaxis for Pneumocystis carinii pneumonia in solid organ transplant recipients: 'as long as the pros outweigh the cons'. Clin Infect Dis 1999; 28: 247-9.
11. Dykewicz CA. Summary of the guidelines for preventing opportunistic infections among haematopoietic stem cell transplant recipients. Clin Infect Dis 2001; 33: 139-44.
12. Pagano L, Fianchi L, Mele L, Girmenia C, Offidani M, Ricci P, et al. Pneumocystis carinii pneumonia in patients with malignant haematological diseases: 10 y experience of infection in GIGEMA centres. Br J Haematol 2002; 117: 379-86.
13. Santos LD, Lacube P, Latouche S, Kac G, Mayaud C, Marteau M, et al. Contribution of dihydropteroate synthase gene typing for Pneumocystis carinii f. sp. hominis epidemiology. J Eukaryot Microbiol 1999; 46: 133-4.
14. Souza JP, Boeckh M, Gooley TA, Flowers ME, Crawford SW. High rates of Pneumocystis carinii pneumonia in allogenic blood and marrow transplant recipients receiving dapsone prophylaxis. Clin Infect Dis 1999; 29: 1467-71.
15. Chung JB, Armstrong K, Schwartz JS, Albert D. Cost-effectiveness of prophylaxis against Pneumocystis carinii pneumonia in patients with Wegener's granulomatosis under immunosuppressive therapy. Arthitis Rheum 2000; 43: 1841-8.
16. Sepkowitz KA, Brown AE, Armstrong D. Pneumocystis carinii pneumonia without acquired immunodeficiency syndrome. Arch Intern Med 1995; 155: 1125-8.
17. Sudhöff T, Arning M, Schneider W. Prophylactic strategies to meet infectious complications in fludarabine-treated CLL. Leukaemia 1997; 11: S38-41.
18. Sepkowitz KA. Opportunistic infections in patients with and patients without acquired immunodeficiency syndrome. Clin Infect Dis 2002; 34: 1098-107.
19. Sepkowitz KA. Pneumocystis carinii pneumonia among patients with neoplastic disease. Sem Resp Infections 1992; 7: 114-21.
20. Browne MJ, Hubbard SM, Longo DL, Fisher R, Wesley R, Ihde DC, et al. Excess prevalence of Pneumocystis carinii pneumonia in patients treated for lymphoma with combination chemotherapy. Ann Intern Med 1986; 104: 338-44.
21. Anaissie EJ, Kontoyannis D, O' Brien S, Kantarjian H, Robertson Lerner S, Keating MJ. Infections in patients with chronic lymphocytic leukaemia treated with fludarabine. Ann Intern Med 1998; 129: 559-66.
22. Roblot F, Le Moal G, Godet C, Hutin P, Texereau M, Boyer E, et al. Pneumocystis carinii infection in patients with haematological malignancies: a descriptive study. J Infect 2003; 47: 19-27.
23. Husain S, Singh N. The impact of novel immunosuppressive agents on infection in organ transplant recipients and the interactions of these agents with antimicrobials. Clin Infect Dis 2002; 35: 53-61.
24. Skarin AT, Rosenthal DS, Moloney WC, Frei E III. Combination chemotherapy of advanced non-Hodgkin's lymphoma with bleomycin, adriamycin, cyclophosphamide, vincristine, and prednisone (BACOP). Blood 1997; 49: 759-70.
25. Bauer KA, Skarin AT, Balikian JP, Garnick MB, Rosenthal DS, Canellos JP. Pulmonary complications associated with combination chemotherapy programmes containing bleomycin. Am J Med 1983; 74: 557-63.
26. Mathew BS, Grossman SA. Pneumocystis carinii prophylaxis in HIV-negative patients with primary CNS lymphoma. Cancer Treat Rev 2003; 29: 105-19.
27. Kritz A, Sepkowitz K, Weiss M, Telford P, Sogoloff H, Kempin S, et al. Pneumocystis carinii pneumonia developing within 1 month of intensive chemotherapy for treatment of acute lymphoblastic leukaemia. N Engl J Med 1991; 325: 661-2.
28. Broyart A, Debard A, Rohrlich P, Rahimy C, Lescoeur B, Vilmer E. When to initiate anti-Pneumocystis carinii prophylaxis in acute lymphoblastic leukaemia treatment? Leukaemia 1994; 8: 216.
29. Chen CS, Boeckh M, Seidel K, Clark JG, Kansu E, Madtes DK, et al. Incidence, risk factors and mortality for pneumonia developing late after haematopoietic stem cell transplantation. Bone Marrow Transplant 2003; 32: 515-22.
30. Klippstein A, Schneider CP, Sayer HG, Hoffken K. Pneumocystis carinii pneumonia as a complication of bendamustine monotherapy in a patient with advanced progressive breast cancer. J Cancer Res Clin Oncol 2003; 129: 316-9.
31. Kane GC, Troshinsky MB, Peters SP, Israel HL. Pneumocystis carinii pneumonia associated with weekly methotrexate: cumulative dose of methotrexate and low CD4+ cell count may predict this complication. Respir Medicine 1993; 87: 153-5.
32. Bergmann L. Present status of purine analogues in the therapy of chronic lymphocytic leukaemias. Leukaemia 1997; 11: S29-34.
33. Morra E, Nosari A, Montillo M. Infectious complications in chronic lymphocytic leukaemia. Haematol Cell Ther 1999; 41: 145-51.
34. Poulsen A, Demeny AK, Bang Plum C, Gjerum Nielsen K, Schmiegelow K. Pneumocystis carinii pneumonia during maintenance treatment of childhood acute lymphoblastic leukaemia. Med Pediatr Oncol 2001; 37: 20-3.
35. Rai KR, Freter CE, Mercier RJ, Cooper MR, Mitchell BS, Stadtmauer EA, et al. Alemtuzumab in previously treated chronic lymphocytic leukaemia patients who also had received fludarabine. J Clin Oncol 2002; 20: 3891-7.
36. Perkins JG, Flynn JM, Howard RS, Byrd JC. Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukaemia and small lymphocytic lymphoma. Cancer 2002; 94: 2033-9.
37. Kulke MH, Vance EA. Pneumocystis carinii pneumonia in patients receiving chemotherapy for breast cancer. Clin Infect Dis 1997; 25: 215-8.
38. Kuitert LM, Harrison AC. Pneumocystis carinii pneumonia as a complication of methotrexate treatment of asthma. Thorax 1991; 46: 936-7.
39. Fenchel K, Bergmann L, Wijermans P, Engert A, Pralle H, Mitrou PS, et al. Clinical experience with fludarabine and its immunosuppressive effects in pretreated chronic lymphocytic leukaemias and low grade lymphomas. Leuk Lymphoma 1995; 18: 485-92.
40. Seymour JF, Grigg AP, Szer J, Fox RM. Fludarabine and mitoxantrone: effective and well-tolerated salvage therapy in relapsed indolent lymphoproliferative disorders. Ann Oncol 2001; 12: 1455-60.
41. Nevez G, Raccurt C, Vincent P, Jounieaux V, Dei-Cas E. Pulmonary colonization with Pneumocystis carinii in human immunodeficiency virus-negative patients: assessing risk with blood CD4+ T-cell counts. Clin Infect Dis 1999; 29: 1331-2.
42. Cobben NA, Drent M, Schols AM, Lamers RJ, Wouters EF, Van Dieijen-Visser MP. Serum lactate dehydrogenase and its isoenzyme pattern in ex-coalminers. Respir Med 1997; 91: 616-23.
43. Benfield TL, Helweg-Larsen J, Bang D, Junge J, Lundgren JD. Prognostic markers of short-term mortality in AIDS-associated Pneumocystis carinii pneumonia. Chest 2001; 119: 844-51.
44. Zahar JR, Robin M, Azoulay E, Fieux F, Nitenberg G, Schlemmer B. Pneumocystis carinii pneumonia in critically ill patients with malignancy: a descriptive study. Clin Infect Dis 2002; 35: 929-34.
45. Bang D, Emborg J, Elkjaer J, Lundgren JD, Benfield TL. Independent risk of mechanical ventilation for AIDS-related Pneumocystis carinii pneumonia associated with bronchoalveolar lavage neutrophilia. Respir Med 2001; 95: 661-5.
46. Mansharamani NG, Garland R, Delaney D, Koziel H. Management and outcome patterns for adult Pneumocystis carinii pneumonia, 1985-1995: comparison of HIV-associated cases to other immunocompromized states. Chest 2000; 118: 704-11.